A detailed history of Schonfeld Strategic Advisors LLC transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Schonfeld Strategic Advisors LLC holds 30,648 shares of BMRN stock, worth $2.03 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
30,648
Previous 204,432 85.01%
Holding current value
$2.03 Million
Previous $16.8 Million 87.2%
% of portfolio
0.02%
Previous 0.12%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$69.02 - $93.84 $12 Million - $16.3 Million
-173,784 Reduced 85.01%
30,648 $2.15 Million
Q2 2024

Aug 14, 2024

BUY
$74.43 - $92.22 $1.63 Million - $2.02 Million
21,940 Added 12.02%
204,432 $16.8 Million
Q1 2024

May 15, 2024

BUY
$83.81 - $99.0 $949,734 - $1.12 Million
11,332 Added 6.62%
182,492 $15.9 Million
Q4 2023

Feb 14, 2024

BUY
$76.22 - $98.51 $5.8 Million - $7.5 Million
76,159 Added 80.17%
171,160 $16.5 Million
Q3 2023

Nov 14, 2023

BUY
$85.07 - $94.48 $3.11 Million - $3.46 Million
36,574 Added 62.6%
95,001 $8.41 Million
Q2 2023

Aug 14, 2023

BUY
$86.68 - $100.3 $3.95 Million - $4.57 Million
45,540 Added 353.38%
58,427 $5.06 Million
Q1 2023

May 15, 2023

SELL
$87.74 - $117.27 $5.04 Million - $6.73 Million
-57,400 Reduced 81.67%
12,887 $1.25 Million
Q4 2022

Feb 14, 2023

SELL
$80.93 - $108.63 $2.15 Million - $2.89 Million
-26,569 Reduced 27.43%
70,287 $7.27 Million
Q3 2022

Nov 14, 2022

BUY
$82.16 - $96.94 $7.73 Million - $9.12 Million
94,063 Added 3367.81%
96,856 $8.21 Million
Q2 2022

Aug 15, 2022

SELL
$71.48 - $86.85 $2.53 Million - $3.08 Million
-35,407 Reduced 92.69%
2,793 $231,000
Q1 2022

May 16, 2022

BUY
$74.28 - $92.69 $2.84 Million - $3.54 Million
38,200 New
38,200 $2.95 Million
Q4 2021

Feb 14, 2022

SELL
$71.72 - $91.47 $2.1 Million - $2.68 Million
-29,300 Closed
0 $0
Q3 2021

Nov 16, 2021

BUY
$74.77 - $85.47 $1.27 Million - $1.45 Million
17,001 Added 138.23%
29,300 $2.27 Million
Q2 2021

Aug 16, 2021

BUY
$75.51 - $84.79 $928,697 - $1.04 Million
12,299 New
12,299 $1.03 Million
Q1 2021

May 17, 2021

SELL
$74.73 - $90.69 $1.39 Million - $1.68 Million
-18,541 Closed
0 $0
Q4 2020

Feb 16, 2021

BUY
$72.61 - $90.2 $1 Million - $1.24 Million
13,788 Added 290.09%
18,541 $1.63 Million
Q3 2020

Nov 16, 2020

SELL
$71.87 - $131.03 $340,304 - $620,427
-4,735 Reduced 49.91%
4,753 $362,000
Q2 2020

Aug 14, 2020

BUY
$79.55 - $124.22 $249,627 - $389,802
3,138 Added 49.42%
9,488 $1.17 Million
Q1 2020

May 15, 2020

BUY
$71.37 - $96.85 $453,199 - $614,997
6,350 New
6,350 $537,000
Q4 2019

Feb 14, 2020

SELL
$64.27 - $86.37 $2.87 Million - $3.86 Million
-44,700 Closed
0 $0
Q3 2019

Nov 14, 2019

BUY
$67.4 - $85.11 $2.49 Million - $3.15 Million
37,000 Added 480.52%
44,700 $3.01 Million
Q2 2019

Aug 14, 2019

BUY
$80.35 - $93.9 $618,695 - $723,030
7,700 New
7,700 $660,000
Q4 2018

Feb 14, 2019

SELL
$80.14 - $106.07 $1.35 Million - $1.79 Million
-16,900 Closed
0 $0
Q3 2018

Nov 14, 2018

SELL
$93.92 - $105.72 $6.47 Million - $7.28 Million
-68,900 Reduced 80.3%
16,900 $1.64 Million
Q2 2018

Aug 14, 2018

BUY
$76.01 - $99.03 $6.52 Million - $8.5 Million
85,800 New
85,800 $8.08 Million

Others Institutions Holding BMRN

About BIOMARIN PHARMACEUTICAL INC


  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $12.3B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Schonfeld Strategic Advisors LLC Portfolio

Follow Schonfeld Strategic Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Schonfeld Strategic Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Schonfeld Strategic Advisors LLC with notifications on news.